113 related articles for article (PubMed ID: 12799622)
1. Oral melphalan as a treatment for platinum-resistant ovarian cancer.
Hasan J; Jayson GC
Br J Cancer; 2003 Jun; 88(12):1828-30. PubMed ID: 12799622
[TBL] [Abstract][Full Text] [Related]
2. Melphalan for the treatment of patients with recurrent epithelial ovarian cancer.
Davis-Perry S; Hernandez E; Houck KL; Shank R
Am J Clin Oncol; 2003 Aug; 26(4):429-33. PubMed ID: 12902900
[TBL] [Abstract][Full Text] [Related]
3. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).
Alici S; Saip P; Eralp Y; Aydiner A; Topuz E
Am J Clin Oncol; 2003 Aug; 26(4):358-62. PubMed ID: 12902885
[TBL] [Abstract][Full Text] [Related]
4. Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study.
Pignata S; Ferrandina G; Scarfone G; Scollo P; Odicino F; Selvaggi L; Katsaros D; Frigerio L; Mereu L; Ghezzi F; Manzione L; Lauria R; Breda E; Marforio G; Ballardini M; Lombardi AV; Sorio R; Tumolo S; Costa B; Magni G; Perrone F; Favalli G;
Oncology; 2006; 71(5-6):320-6. PubMed ID: 17878745
[TBL] [Abstract][Full Text] [Related]
5. Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.
Pignata S; Ferrandina G; Scarfone G; Scollo P; Odicino F; Cormio G; Katsaros D; Frigerio L; Mereu L; Ghezzi F; Manzione L; Lauria R; Breda E; Alletti DG; Ballardini M; Vernaglia A; Sorio R; Tumolo S; Musso P; Magni G; Pisano C; Morabito A
Crit Rev Oncol Hematol; 2009 Sep; 71(3):233-41. PubMed ID: 19179095
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of melphalan as a single-agent infused over a 24-hour period with individual adapted dosing in patients with recurrent epithelial ovarian cancer.
Mougenot P; Fabbro M; Bressolle F; Pouessel D; Culine S; Pinguet F
Oncol Rep; 2006 Jan; 15(1):237-41. PubMed ID: 16328062
[TBL] [Abstract][Full Text] [Related]
8. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.
Cree IA; Kurbacher CM; Lamont A; Hindley AC; Love S;
Anticancer Drugs; 2007 Oct; 18(9):1093-101. PubMed ID: 17704660
[TBL] [Abstract][Full Text] [Related]
9. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.
Matsumoto A; Higuchi T; Yura S; Mandai M; Kariya M; Takakura K; Fujii S
J Obstet Gynaecol Res; 2006 Dec; 32(6):580-7. PubMed ID: 17100820
[TBL] [Abstract][Full Text] [Related]
10. Management of recurrent ovarian carcinoma: current status and future directions.
Martin LP; Schilder RJ
Semin Oncol; 2009 Apr; 36(2):112-25. PubMed ID: 19332246
[TBL] [Abstract][Full Text] [Related]
11. Weekly topotecan for recurrent platinum resistant ovarian cancer.
Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy in patients with recurrent or refractory epithelial ovarian cancer.
Satthapong D; Tangjitgamol S; Manusirivithaya S; Pataradool K
J Med Assoc Thai; 2007 Mar; 90(3):411-9. PubMed ID: 17427513
[TBL] [Abstract][Full Text] [Related]
13. Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up.
; Chou HH; Wang KL; Chen CA; Wei LH; Lai CH; Hsieh CY; Yang YC; Twu NF; Chang TC; Yen MS
Gynecol Oncol; 2006 Jun; 101(3):423-8. PubMed ID: 16325239
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer.
Levy T; Inbar M; Menczer J; Grisaru D; Glezerman M; Safra T
Gynecol Oncol; 2004 Dec; 95(3):686-90. PubMed ID: 15581982
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study.
Fracasso PM; Blessing JA; Morgan MA; Sood AK; Hoffman JS
J Clin Oncol; 2003 Aug; 21(15):2856-9. PubMed ID: 12885801
[TBL] [Abstract][Full Text] [Related]
16. Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy.
Colombo N; Gore M
Crit Rev Oncol Hematol; 2007 Nov; 64(2):129-38. PubMed ID: 17566758
[TBL] [Abstract][Full Text] [Related]
17. Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer.
Le T; Hopkins L; Baines KA; Rambout L; Al Hayki M; Kee Fung MF
Gynecol Oncol; 2006 Jul; 102(1):49-53. PubMed ID: 16375951
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
[TBL] [Abstract][Full Text] [Related]
19. The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer.
Cadron I; Leunen K; Amant F; Van Gorp T; Neven P; Vergote I
Gynecol Oncol; 2007 Aug; 106(2):354-61. PubMed ID: 17499348
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum.
Markman M; Webster K; Zanotti K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 2004 Aug; 94(2):404-8. PubMed ID: 15297180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]